Nantahala Capital Management LLC bought a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 600,000 shares of the company's stock, valued at approximately $9,864,000. Nantahala Capital Management LLC owned approximately 1.12% of Upstream Bio at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. US Bancorp DE bought a new position in shares of Upstream Bio in the fourth quarter valued at $27,000. Legal & General Group Plc acquired a new stake in shares of Upstream Bio during the fourth quarter worth $28,000. Summit Investment Advisors Inc. purchased a new stake in shares of Upstream Bio during the fourth quarter valued at $30,000. Tower Research Capital LLC TRC acquired a new position in shares of Upstream Bio in the 4th quarter valued at $47,000. Finally, Corebridge Financial Inc. purchased a new position in Upstream Bio in the 4th quarter worth about $142,000.
Upstream Bio Price Performance
NASDAQ UPB traded down $0.36 on Friday, hitting $8.64. 484,378 shares of the company were exchanged, compared to its average volume of 324,226. Upstream Bio, Inc. has a twelve month low of $5.14 and a twelve month high of $29.46. The company's 50 day moving average price is $7.96 and its 200-day moving average price is $14.14.
About Upstream Bio
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
